Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Michele GuliziaAndrea Grammatico

Abstract

Many sinus node disease (SND) patients suffer from atrial fibrillation (AF). Anti-arrhythmic drugs (AADs) are the therapeutic mainstay for AF prophylaxis. The PITAGORA trial has a multicentre, prospective, randomized, single blind design to compare amiodarone with Class IC AADs in patients who have an AF history and are paced for SND. Starting from January 2001, 176 patients received a Medtronic AT500 pacemaker. AADs were randomly assigned with a 3 : 2 ratio between Class III and Class IC. Randomization was stratified in order to assign two patients to amiodarone and one patient to sotalol every three Class III AAD patients. After a 5-month observational period, Ramp or Burst+ ATP therapies were enabled in a randomized way, maintained for 4 months, and then crossed over. Total follow-up period is 21 months. The primary long-term objective is to show the non-inferiority of IC AADs compared with amiodarone in terms of time to first occurrence of a composite endpoint (death, atrial cardioversion, hospitalizations due to AF or heart failure, or change of AADs). Data will be analysed on an intention-to-treat basis. The primary short-term objective is to compare Ramp vs. Burst+ efficacy in terminating atrial tachyarrhythmias treated ...Continue Reading

References

Jun 24, 1992·JAMA : the Journal of the American Medical Association·A T GosselinkK I Lie
Mar 1, 1989·Progress in Cardiovascular Diseases·H A Kopelman, L N Horowitz
Apr 1, 1989·The American Journal of Cardiology·S J Connolly, D L Hoffert
Jan 1, 1989·Journal of Clinical Epidemiology·R Makuch, M Johnson
Oct 1, 1988·Journal of the American College of Cardiology·E M AntmanP L Friedman
Oct 1, 1983·American Heart Journal·T B GraboysB Lown
Mar 1, 1982·Circulation·L E Hinkle, H T Thaler
Mar 1, 1993·The American Journal of Cardiology·S C ReimoldE M Antman
Jul 6, 1996·BMJ : British Medical Journal·B JonesA F Ebbutt
Jun 1, 1997·Pacing and Clinical Electrophysiology : PACE·M M Gallagher, A J Camm
Sep 1, 1997·Journal of the American College of Cardiology·V R VorperianC T January
Oct 7, 1997·Lancet·S M NarayanJ M Smith
Sep 28, 1998·Statistics in Medicine·J Röhmel
Mar 31, 2000·American Heart Journal·J P Siegel
Apr 5, 2000·International Journal of Cardiology·M F Piepoli, A Capucci
Apr 5, 2001·The New England Journal of Medicine·R H Falk
Nov 9, 2001·Journal of Cardiovascular Electrophysiology·C W IsraelUNKNOWN AT500 Verification Study Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.